How to Find an Actinium Pharmaceuticals Job: What You Need to Know
“This is a fantastic opportunity,” said Karen Rochard, president of the American Association of Actinitis Mediators.
“This has the ability to make us one of the top 10 companies in the world.”
But she added that the pay and benefits for the doctors and nurses are not always what they are worth.
The compensation is based on a 10-year average of sales, but sometimes the same doctor may make twice that amount in a given year, Rochart said.
“It is not as much as some other countries, but we’re a very small company.
So it is really difficult to get a full picture.”
Rochard said the AMA has seen a sharp decline in the number of people applying for jobs at the drug company.
She said her organization has already made several calls to prospective hires, and she is calling for the AMA to get rid of the 10-figure salary.
The AMA, which has been a member of the FDA since 1986, has been critical of the drug companies that make their products, including Pfizer, AstraZeneca and AbbVie.
The AMA has been lobbying for the FDA to require more transparency from drugmakers and the agency has backed off from some of its earlier demands, such as requiring a two-year waiting period before a drug can be approved for a particular type of disease.
But the AMA remains staunchly opposed to more FDA oversight of companies like Actinio, Rothstein said.
“This is the one that we feel has really broken the back of our industry,” she said.
Rothstein also called on the FDA not to approve the drug until it can prove that the drug is safe and effective.
That’s a tougher sell in the United States than in Europe, where drugmakers have long been able to market drugs with minimal risk of side effects.
Actinia was approved in Europe in 2008.
Rochards employer, AuberDynamics, is also a member and a major player in the drug industry, but she said the job is very competitive.
“Actinium is the most valuable pharmaceutical company in the US,” she told NBC News.
“We don’t get a lot of respect in the industry.
But it’s not about us, it’s about the industry.”